[Federal Register Volume 85, Number 71 (Monday, April 13, 2020)]
[Notices]
[Pages 20507-20508]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-07707]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of an Exclusive Patent License: 
Interinstitutional Agreement--Institution Lead: Graphene Oxide-
Polycarbonate Track-Etched Nanosieve Platform for Sensitive Detection 
of Human Immunodeficiency Virus Envelope Glycoprotein

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Cancer Institute, an institute of the National 
Institutes of Health, Department of Health and Human Services, is 
contemplating the grant of an Exclusive Patent License to practice the 
inventions embodied in the Indian Patent Applications listed in the 
Supplementary Information section of this notice to Chaudhary Charan 
Singh Haryana Agricultural University (CCSHAU) located in Hisar, India.

DATES: Only written comments and/or applications for a license which 
are received by the National Cancer Institute's Technology Transfer 
Center on or before April 28, 2020 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
and comments relating to the contemplated an Exclusive Patent License 
should be directed to: Jasmine J. Yang, Ph.D., (Senior) Licensing and 
Patenting Manager, NCI Technology Transfer Center, 9609 Medical Center 
Drive, RM 1E530 MSC 9702, Bethesda, MD 20892-9702 (for business mail), 
Rockville, MD 20850-9702 Telephone: (240)-276-5530; Facsimile: (240)-
276-5504 Email: [email protected].

SUPPLEMENTARY INFORMATION: 

Intellectual Property

    Indian Patent Application Serial No. 201711002764, filed February 
24, 2017 entitled ``Graphene oxide-polycarbonate track-etched nanosieve 
platform for sensitive detection of human immunodeficiency virus 
envelope glycoprotein.''
    The patent rights in these inventions have been assigned and/or 
exclusively licensed to the CCS Haryana Agricultural University and 
Government of the United States of America as represented by the 
Secretary, Department of Health & Human Services.
    The prospective patent license will be for the purpose of 
consolidating the patent rights to CCSHAU, the co-owners of said 
rights, for commercial development and marketing. Consolidation of 
these co-owned rights is intended to expedite development of the 
invention, consistent with the goals

[[Page 20508]]

of the Bayh-Dole Act codified as 35 U.S.C. 200-212.
    The prospective patent license will be an exclusive in India and 
may be limited to those fields of use commensurate in scope with the 
patent rights. It will be sublicensable, and any sublicenses granted by 
CCSHAU will be subject to the provisions of 37 CFR part 401 and 404.
    This technology discloses a graphene oxide-polycarbonate nanosieve 
electrochemical biosensor for the detection of HIV envelope 
glycoprotein. The nanosieve is comprised of a polycarbonate membrane 
layered with graphene oxide laminate, which is conjugated to a 
bispecific tetravalent antibody, ``2Dm2m'', comprised of CD4 fused to a 
human domain targeting HIV-1 coreceptor binding domain that has high 
affinity to the HIV envelope glycoprotein gp140. The nanosieve is 
fitted between two Ag/AgCl electrodes to form an electrochemical 
nanobiosensor capable of detecting HIV virus (see attached figures). 
Binding of the HIV gp140 to 2Dm2m reduces the ionic current through the 
nanosieve biosensors, which functions as the marker of HIV presence. 
The biosensor has the potential to be a low-cost, portable and quick 
method for HIV viral load detection.
    This notice is made in accordance with 35 U.S.C. 209 and 37 CFR 
part 404. The prospective exclusive license will be royalty bearing, 
and the prospective exclusive license may be granted unless within 
fifteen (15) days from the date of this published notice, the National 
Cancer Institute receives written evidence and argument that 
establishes that the grant of the license would not be consistent with 
the requirements of 35 U.S.C. 209 and 37 CFR part 404.
    In response to this Notice, the public may file comments or 
objections. Comments and objections, other than those in the form of a 
license application, will not be treated confidentially, and may be 
made publicly available.
    License applications submitted in response to this Notice will be 
presumed to contain business confidential information and any release 
of information in these license applications will be made only as 
required and upon a request under the Freedom of Information Act, 5 
U.S.C. 552.

    Dated: April 2, 2020.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer 
Institute.
[FR Doc. 2020-07707 Filed 4-10-20; 8:45 am]
 BILLING CODE 4140-01-P